NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced that it has regained compliance with Nasdaq’s continued listing requirement. NexMed received a letter dated February 6, 2006 from the NASDAQ Hearings Department stating that it has demonstrated full compliance with requirements necessary for continued listing on the Nasdaq National Market.
